Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 9/20 | 0.38 |
| ▸ | RAB9A | P51151 | 9/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838719 | 0.90 | MAPK14 (0.42) | ALDH1A1KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL849766 | 0.84 | MAPT (0.46) | ALDH1A1KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL838447 | 0.82 | RAB9A (0.40) | ALDH1A1KDM4EHSD17B10TSHRNPC1 | |
| SCHEMBL25343285 | 0.82 | SLC2A1 (0.43) | ALDH1A1KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL839501 | 0.82 | MAPK14 (0.48) | ALDH1A1KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL839999 | 0.78 | SLC2A1 (0.46) | ALDH1A1KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL6204755 | 0.78 | GSK3B (0.54) | ALDH1A1KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL31337054 | 0.76 | ALDH1A1 (0.67) | ALDH1A1KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL6282033 | 0.76 | ALDH1A1 (0.67) | ALDH1A1KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL839315 | 0.76 | GCK (0.45) | ALDH1A1KDM4EHSD17B10TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | ALDH1A1 1918/4885KDM4E 3541/4885HSD17B10 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.